Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit, and clinical implementation for heart failure with preserved function.
Key findingReview of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit
What the researchers found
Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit, and clinical implementation for heart failure with preserved function.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Trials reviewed: SUSTAIN 6, PIONEER 6, STEP HFpEF, STEP HFpEF DM. Focus on obesity-related HFpEF.
How the study worked
In publication.
Who was studied
Patients with heart failure with preserved ejection fraction (HFpEF), particularly those with obesity and/or type 2 diabetes
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.
Cureus, 17(7), e87605
Citation
Arty, Fnu; Shreya, Devarashetty; Chaudhry, Aleeza; Sohini, Sarkar. (2025). Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.. Cureus, 17(7), e87605. https://doi.org/10.7759/cureus.87605